-
TSMC CEO Discovers Signs of a Bottom in the Chip Industry
Taiwan Semiconductor Manufacturing Co., the world's largest chip foundry, said on Thursday that there are signs that a difficult year for the chip industry may be coming to an end. With the decline i ... -
Is the new indication for the "slimming elixir" on the way? Senior executives revealed that they will see the outcome within six months
On Thursday (November 2nd) local time, executives from Danish pharmaceutical giant Novo Nordisk stated that their developed heavyweight weight weight loss drug "Wegovy" may receive approval from the ... -
Lilly Tilpotide Weight Loss Indications Approved in the United States Industry: Weight loss pills are about to face a "cola battle"
On November 8th local time, Lilly announced that its GLP-1R/GIPR dual target agonist Tirzepatide injection has been approved by the FDA for weight loss indications. Affected by this news, overseas bi ... -
Eli Lilly Pharmaceuticals Engliflozin has been approved for indications for adult chronic kidney disease in China
On November 24, Lilly Pharmaceutical and Boehringer Ingelheim jointly announced that Outangjing& Reg; The new indication of Engliflozin has been approved by the National Drug Administration of China ... -
GlaxoSmithKline: Indications for adult lupus nephritis with Belizumab for injection included in the 2023 National Medical Insurance Catalogue
GlaxoSmithKline (GSK) China announced that its biopharmaceutical product, Belizumab for Injection, for adult lupus nephritis (LN), has been included in the National Basic Medical Insurance, Work Inju ... -
Is the new era of healthcare coming at a fast pace? New indications for "gene scissors" have been approved in the United States ahead of schedule
On Tuesday (January 16th) local time, American biotech company Vertex Pharmaceuticals announced on its official website that the US Food and Drug Administration (FDA) approved its Casgevy therapy for ... -
Sanofi: New indications for dabitol have been given priority review by the US FDA
On February 23rd, Sanofi announced that the US Food and Drug Administration (FDA) had granted dabitol& Reg; Priority review of the application for market authorization (sBLA) for the sixth potential ...- stevenbaul
- 2024-2-23
- サポート
- に反対
- 返信
- コレクション
-
BeiGene: The first indication approved for tirizizumab in the United States
On March 15th, Baekje announced that the US Food and Drug Administration (FDA) has approved tirizizumab (Chinese trade name: Baekzean®; English trade name: TEVIMBRA®) as a monotherapy for adu ... -
Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
On June 25th, Novo Nordisk announced that its new indication for Smegglutide Injection has been approved by the National Medical Products Administration for listing (trade name: Novo Nordisk) as an a ... -
Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
On June 25th, Red Star Capital Bureau reported that the National Medical Products Administration recently approved the listing application of Novo Nordisk's research and production of Novo Nordisk's ... -
Novo Nordisk Smegglutide Weight Loss Indications Approved in China, Next Battle is Capacity
On June 25th, Novo Nordisk China announced that the National Medical Products Administration (NMPA) had recently approved the marketing application of Novo Nordisk's research and production of Novo N ... -
Eli Lilly and Predator Peptide Approved for Long term Weight Management Indications in China
Today, the long-term weight management indication of Eli Lilly Mufengda (Tenpo Peptide Injection) has been approved by the National Medical Products Administration. Mufengda is the first and currentl ... -
Dexmedetomidine monoclonal antibody adds new indications for advanced gastric cancer
New Beijing News (Reporter Zhang Xiulan) On August 13th, the official website of the National Medical Products Administration (NMPA) showed that the antibody coupled drug (ADC) Uxostat (injectable tr ... -
Novartis antibody new drug Busizumab injection new indication declared for market in China
On October 12th, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Novartis' application for the listing of Busizumab ... -
BeiGene: Several new indications for commercial products have been included in the 2024 National Medical Insurance Drug Catalog
On November 28th, BeiGene announced that its independently developed anti-PD-1 antibody Baize'an (Trastuzumab Injection) and BTK inhibitor Baiyueze (Zebutinib Capsules) have been added to the new ver ... -
AbbVie: Two new indications for Ruifu (Upatinib Extended Release Tablets) have been added to the national medical insurance catalog in China
On November 28th, AbbVie China announced that the two newly approved indications for the immune innovation product Ruifu (Upatinib Extended Release Tablets) in 2023 have entered the new version of th ... -
Multiple new indications for Merck drugs approved for market in China
On December 10th, Merck announced that its PD-1 inhibitor pembrolizumab (trade name: Kelida®) Approved by the National Medical Products Administration, the combination of radiotherapy and chemoth ... -
BeiGene and BeiZeAn are approved for new indications in the United States
Recently, BeiGene announced that the US Food and Drug Administration (FDA) has approved the use of BeiGene (Trastuzumab) in combination with platinum and fluorouracil chemotherapy for first-line trea ...